Business Context and Reporting Period
This Form 8-K was filed by Verrica Pharmaceuticals Inc. on July 24, 2025, with the report date of July 30, 2025. The filing addresses a critical corporate governance event regarding the company's continued listing on The Nasdaq Global Market under the ticker symbol VRCA.
Key Financial Metrics
This filing is a current report regarding a listing status event and does not contain financial statements. Consequently, data on revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Events
- Nasdaq Delisting Notice: On July 24, 2025, Nasdaq notified the company that its securities were subject to delisting for failing to maintain the $1.00 minimum closing bid price requirement over a 30-business day period ending prior to the 180-day grace period expiration.
- Reverse Stock Split: To address the non-compliance, the company effected a 1-for-10 reverse stock split on July 24, 2025. Trading on a split-adjusted basis commenced on July 25, 2025.
- Compliance Status: As of July 29, 2025, the closing bid price was $6.24 per share. The company had achieved four consecutive business days of compliance with the $1.00 minimum bid price requirement.
Outlook, Management Commentary, and Risks
Management intends to request a hearing before a Nasdaq Hearings Panel to stay the delisting process, though the reverse split has already restored the bid price to compliant levels. The company plans to request a formal bid price compliance determination and cancellation of the hearing after ten consecutive trading days of compliance. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ due to risks related to the trading price of the common stock and other factors disclosed in the company's Form 10-K.
Investor Verification Checklist
- Verify the current trading status of VRCA on Nasdaq to confirm the delisting stay is active.
- Monitor the stock price for the next six trading days to ensure the company reaches the required 10 consecutive days of compliance above $1.00.
- Review the company's most recent Form 10-K and 10-Q for financial health metrics, as this 8-K contains no financial data.
- Confirm the final outcome of the Nasdaq Hearings Panel request, if the company proceeds with it despite the price recovery.